Florida Senate - 2004

 $\mathbf{B}\mathbf{y}$ the Committee on Health, Aging, and Long-Term Care; and Senator Margolis

	317-954-04
1	A bill to be entitled
2	An act relating to the sale of products
3	containing ephedrine; amending s. 499.033,
4	F.S.; prohibiting the sale or delivery of
5	products containing ephedrine over the counter
6	without a prescription, subject to certain
7	exceptions; repealing s. 501.0583, F.S.,
8	relating to selling, delivering, bartering,
9	furnishing, or giving weight-loss pills to
10	persons under age 18; providing an effective
11	date.
12	
13	Be It Enacted by the Legislature of the State of Florida:
14	
15	Section 1. Section 499.033, Florida Statutes, is
16	amended to read:
17	499.033 Ephedrine; prescription requiredEphedrine
18	is declared to be a prescription drug.
19	(1) Except as provided in subsection (2), <u>a person may</u>
20	not sell or deliver over the counter any product intended for
21	ingestion by humans which that contains any quantity of
22	ephedrine, a salt of ephedrine, an optical isomer of
23	ephedrine, or a salt of an optical isomer of ephedrine <u>,</u>
24	including any part of the plant genus ephedra or the plant
25	genus sida cordifolia, and any species thereof, unless may be
26	dispensed by a duly licensed pharmacist or dispensing
27	practitioner and only upon the prescription of a duly licensed
28	practitioner authorized by the laws of the state to prescribe
29	medicinal drugs.
30	(2) A product containing ephedrine described in
31	paragraphs (a)-(e) is exempt from subsection (1) if it may
	1
CODING . Words stricken are deletions; words underlined are additions	

CODING:Words stricken are deletions; words underlined are additions.

1 lawfully be sold over the counter without a prescription under 2 the federal act; is labeled and marketed in a manner 3 consistent with the pertinent United States Food and Drug 4 Administration Over-the-Counter Tentative Final or Final 5 Monograph; and is manufactured and distributed for legitimate 6 medicinal use in a manner that reduces or eliminates the 7 likelihood of abuse, when considered in the context with: the 8 package sizes and the manner of packaging of the drug product; the name and labeling of the product; the manner of 9 10 distribution, advertising, and promotion of the product; the 11 duration, scope, health significance, and societal cost of abuse of the particular product; the need to provide medically 12 13 important ephedrine-containing therapies to the public for United States Food and Drug Administration approved 14 indications on an unrestricted, over-the-counter basis; and 15 other facts as may be relevant to and consistent with public 16 17 health and safety. (a) Solid oral dosage forms that combine active 18 19 ingredients in the following ranges for each dosage unit: 20 Theophylline (100-130mg), ephedrine (12.5-24mg). 1. 2. Theophylline (60-100mg), ephedrine (12.5-24mg), 21 22 guaifenesin (200-400mg). Ephedrine (12.5-25mg), guaifenesin (200-400mg). 23 3. 24 4. Phenobarbital (not greater than 8mg) in combination 25 with the ingredients of subparagraph 1. or subparagraph 2. (b) Liquid oral dosage forms that combine active 26 27 ingredients in the following ranges for each (5ml) dose: 28 Theophylline (not greater than 45mg), ephedrine 1. 29 (not greater than 36mg), guaifenesin (not greater than 100mg), 30 phenobarbital (not greater than 12mg). 31

2

CODING: Words stricken are deletions; words underlined are additions.

1 2. Phenylephrine (not greater than 5mg), ephedrine 2 (not greater than 5mg), chlorpheniramine (not greater than 3 2mg), dextromethorphan (not greater than 10mg), ammonium 4 chloride (not greater than 40mg), ipecac fluid extract (not 5 greater than 0.005ml). б (c) Anorectal preparations containing less than 5 7 percent ephedrine. Nasal decongestant compounds, mixtures, or 8 (d) 9 preparations containing 0.5 percent or less ephedrine. 10 (e) Any drug product containing ephedrine that is marketed pursuant to an approved new drug application or legal 11 equivalent under the federal act. 12 The department may administer implement this 13 (3) 14 section by rule. 15 Section 2. Section 501.0583, Florida Statutes, as 16 created by section 1 of chapter 2003-24, Laws of Florida, is 17 repealed. 18 Section 3. This act shall take effect July 1, 2004. 19 STATEMENT OF SUBSTANTIAL CHANGES CONTAINED IN COMMITTEE SUBSTITUTE FOR 20 Senate Bill 446 21 22 The committee substitute provides a definition of ephedra and sida cordifolia and clarifies that the prohibition on the sale and delivery of ephedra without a prescription only applies to products containing ephedra that are intended for ingestion by 23 24 25 humans. The bill repeals s.501.0583, F.S., which prohibits the selling, delivering, bartering, furnishing, or giving of weight-loss pills to persons under age 18. 26 27 28 29 30 31 3

CODING: Words stricken are deletions; words underlined are additions.